Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Wakunaga Pharmaceutical Co., Ltd. | INDUSTRY |
The purpose of the study is to determine the effect of monascus garlic fermented extract on serum lipid concentrations in subjects with moderately elevated serum triglyceride.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Monascus Garlic Fermented Extract | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Monascus Garlic Fermented Extract | Dietary Supplement |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Fasting triglyceride level | Every 4 weeks (Overall 20 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| Abdominal circumference | Every 4 weeks (Overall 20 weeks) | |
| Visceral fat area by CT scan | Week 0 and Week 12 | |
| Serum total cholesterol and LDL cholesterol levels |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hiroshima University | Hiroshima | Hiroshima | 734-8551 | Japan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22041543 | Derived | Higashikawa F, Noda M, Awaya T, Ushijima M, Sugiyama M. Reduction of serum lipids by the intake of the extract of garlic fermented with Monascus pilosus: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2012 Apr;31(2):261-6. doi: 10.1016/j.clnu.2011.10.008. Epub 2011 Oct 29. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015228 | Hypertriglyceridemia |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Dietary Supplement |
|
| Every 4 weeks (Overall 20 weeks) |
| Serum adiponectin level | Week 0 and Week 12 |
| D009750 |
| Nutritional and Metabolic Diseases |